FDA approves 1st needle-free alternative to EpiPens

The Food and Drug Administration (FDA) has granted approval for Neffy, the first needle-free treatment for anaphylaxis, a severe allergic reaction that can be life-threatening. This new medication contains epinephrine, the same active ingredient found in EpiPens, which is crucial for managing allergic reactions. Epinephrine works by relaxing airway muscles and constricting blood vessels, effectively countering the dangerous symptoms associated with anaphylaxis, such as airway spasms and a significant drop in blood pressure. Dr. Kelly Stone, associate director of the FDA's Division of Pulmonology, Allergy and Critical Care, emphasized the significance of this approval, stating that Neffy represents a major advancement in the treatment of anaphylaxis. The nasal spray format may help eliminate barriers to immediate treatment, making it easier for patients to respond quickly during an allergic emergency. Neffy is designed for single-dose administration into one nostril, with the option for a second dose if symptoms persist. This second dose would require a separate spray bottle and should be administered in the opposite nostril. However, the FDA advises that patients experiencing anaphylaxis should seek emergency medical assistance for monitoring and potential further treatment. Healthcare providers are encouraged to discuss the use of Neffy with patients who have a history of severe allergies, ensuring they are well-informed about this new treatment option and its proper use.